- The investment totals over 40 million euros.
- Construction starts June 2017, managed by Project Management Group.
- Completion is scheduled for Q2 FY2018, with operations starting in the second half of FY2018.
- The facility will produce NINLARO® for global markets.
Investment and Job Creation
Takeda Pharmaceutical Company Limited is expanding its Grange Castle site in Ireland with a new high-containment production facility. The investment, announced by Ireland’s Minister for Jobs, Enterprise and Innovation, Mary Mitchell O’Connor TD, will create approximately 40 new jobs over the next two years.
Construction and Management
Construction of the new facility begins in June 2017 and will be managed by Project Management Group. The total investment for the project exceeds 40 million euros. The plant is scheduled for completion in Q2 FY2018, with operations commencing in the second half of FY2018.
Facility Features
The new production facility will be unique, housing Drug Substance, Drug Product, Primary and Secondary Packaging, and QC processes all under one roof. This integration aims to streamline production and enhance efficiency.
Product Focus
The facility will be dedicated to manufacturing NINLARO®, Takeda’s oncology product. NINLARO® is the first and only once-weekly oral proteasome inhibitor approved for the treatment of multiple myeloma in patients who have received at least one prior therapy. It has received approvals from the U.S. FDA, the Japanese Ministry of Health, Labour and Welfare, and the European Commission, with additional applications submitted to other regulatory authorities worldwide.
